

1 Article

2 The effects of a pine bark extract on exercise 3 performance and post exercise inflammation, 4 oxidative stress, muscle soreness and damage

5 Randy Aldret ^{1,*} and David Bellar ¹

6 ¹ University of Louisiana at Lafayette

7 * Correspondence: raldret@louisiana.edu; Tel.: +01-337-482-5681

8

9 **Abstract:** The purpose of the present study was to examine if 14 days of supplementation
10 with a pine bark extract leading up to and following an exercise test would increase performance and
11 reduce biomarkers associated with muscle damage, inflammation and oxidative stress. The study
12 used a double-blind, placebo controlled, cross-over design. Participants ingested either 800mg pine
13 bark extract or placebo for 14 days prior to the first exercise trial and for 2 days post-exercise. On the
14 exercise day, participants submitted a pre-exercise blood sample, then completed a VO₂ peak test
15 until volitional failure. A post-blood sample was collected 1 hour after completion of exercise.
16 Participants returned at 24 & 48 hours after the exercise testing for measures of muscle pain in the
17 lower body using an algometer. Participants then had a 7-day washout period before beginning to
18 crossing over to the alternate treatment. Analysis via ordinal regression demonstrated a significant
19 difference in oxidative stress in the pine bark extract group compared to placebo (ChiSq = 2.63;
20 p=0.05). The pine bark extract was effective at affording protection from oxidative stress post exercise.
21 Further work should be undertaken to evaluate the findings with other exercise modes or in
22 participants with known metabolic syndrome.

23

24 **Keywords:** Pine bark extract, Oxidative stress, Muscle damage

25

26 1. Introduction

27 While exercise has multiple known health benefits, there are consequences to prolonged bouts
28 of exercise. High muscle forces damage the sarcolemma initiating the release of cytosolic enzymes
29 and myoglobin, further damaging muscle contractile fibrils and noncontractile structures.
30 Metabolites such as calcium accumulate to abnormal levels in the muscle cell to produce more cell
31 damage and reduced force capacity[1,2]. At this point, the inflammatory process begins, allowing
32 muscle tissue to heal and adapt to protect from subsequent exercise.

33 The contraction of skeletal muscle also generates free radicals, and resulting in oxidative damage
34 to the cell [3]. The primary free radicals generated in cells are superoxide (O₂^{•-}) and nitric oxide (NO).
35 Dismutation of superoxide provides a major source of hydrogen peroxide (H₂O₂) in cells. Hydrogen
36 peroxide is cytotoxic, and readily generates hydroxyl radicals in specific circumstances. Hydroxyl

37 radicals damage molecules close to the site of their generation and are considered the most damaging
38 reactive oxygen species (ROS) present in biological materials[3].

39

40 1.1 Description of French Maritime pine bark

41 French Maritime pine bark (*Pinus P.*) has many purported pharmacological benefits on multiple
42 physiological functions. Most commercial formulations contain 65-75% procyanidins, with phenolic
43 acids making up the remainder [4]. Procyanidins are biopolymers of catechin and epicatechin
44 subunits which are recognized as important constituents in human nutrition. The phenolic acids are
45 derivatives of benzoic and cinnamic acids, specifically, feurlic acid and taxifolin [5].

46

47 1.2 *Pinus P.* potential benefits during exercise

48 The primary mechanism of *Pinus P.* is to increase serum levels of Nitric Oxide (NO) via
49 conversion of NO to superoxide and prolonging the half-life of NO [6], and stimulating Nitric Oxide
50 Synthase (NOS) enzyme [7]. Standard dosing for *Pinus P.* is 100-200 mg daily, but doses as low as 40-
51 60 mg daily have been shown as beneficial if taken over long periods of time. Nishioka et al (2007)
52 found "180 mg daily for 2 weeks is associated with an augmentation of an acetylcholine-induced
53 blood vessel relaxation via NO *in vivo*"[8]. During inflammation, *Pinus P.* metabolites inhibit nitrite
54 production with near absolute suppression of NO at 50mcg/mL, which is a 20-fold increase in potency
55 over hydrocortisone [9].

56 Similarly, *Pinus P.* is able to sequester superoxide, hydroxyl, and free oxygen radicals [10-12].
57 Protective effects against hydrogen peroxide and lipid peroxidation in red blood cells [13], and a
58 reduction in the accumulation of oxidatively modified proteins as also been purported [14]. 200mg
59 of *Pinus P.* in coronary artery disease (CAD) patients is able to decrease levels of 15-F(2t)-Isoprostane
60 by 7% after 8 weeks, suggesting a lowering of oxidation [15].

61

62 1.3 Other Purported Health Benefits

63 1.3.1 Cardiovascular and Neurological

64 In patients with CAD, daily dosing of *Pinus P.* was associated with an improvement in blood
65 flow of 32% [15]. *Pinus P.* also demonstrated a 25% inhibition of platelet aggregation [16], and higher
66 doses (>350mg) noted a decrease in LDL-C and total cholesterol [17].

67 In a study of 61 children with confirmed ADHD, a dose of 1mg/kg daily for 4 weeks was
68 associated with positive changes in hyperactivity and attention versus baseline and placebo [18], and
69 the results were replicate again in an 8-week study of otherwise healthy students [19].

70

71 1.3.2 Obesity and Oxidation

72 *Pinus P.* was previously found to possess lipolytic capabilities [20] but the mechanism is
73 concentration-dependent [21]. The proposed mechanism of this property in suppression of the
74 mRNA levels of fat accumulation genes, specifically CEBP-A, PPAR- γ , aP2, along with G6PDH
75 mRNA suppression during adipogenesis with dosages of 100-200 mcg/mL [22]. Increases in
76 superoxide dismutase and glutathione peroxide at these same dose level were also noted in this
77 study.

78

79 1.3.3 Diabetes

80 While a 12-week study failed to demonstrate any alteration in basal insulin or secretion rates in
81 Type II diabetics, a reduction was shown in HbA1c (0.8%) and overall blood glucose [23]. A follow-
82 up 12-week study noted a similar decrease in HbA1c, with a reduction in blood glucose beginning as
83 early as week 8 of the study [24]. In an animal model study of Type I diabetes, Diabetes was induced
84 in rats via injection of streptozotocin followed by free access to 5% glucose. *Pinus P.* was then given
85 to the rats for 4 weeks, then sacrificed for pancreas and liver assays. The group of rats injected daily
86 with *Pinus P.* demonstrated attenuation changes in blood glucose, HbA1c, hepatic glycogen and
87 insulin of the rats [25].

88

89 1.4 Purpose of the Study

90 The purpose of the study was to determine if 14 days of supplementation with *Pinus P.* leading
91 up to an exercise test and two days of post-exercise supplementation would increase performance
92 and reduce biomarkers associated with muscle damage inflammation and oxidative stress.

93

94 2. Materials and Methods

95 2.1 Participants

96 For the investigation, 20 apparently healthy college males were recruited out of various
97 kinesiology classes at a university in the south United States. Participants were 22.7 years (± 3.9 yrs),
98 with body height of 178.1 cm (± 7.9 cm), and body mass of 82.9 kg (± 13.5 kg). The study group was
99 physically active and engaged in regular exercise 4.3 days/week ($\pm .8$ days/week), a relative body fat
100 of 16.7% ($\pm 7.4\%$), and average cardiovascular capacity of 30.0 ml/kg/min (± 7.0 ml/kg/min).

101 The participants gave written informed consent and reported to the Human Performance Lab
102 for an initial visit where anthropometric measures were collected. All participants gave written
103 informed consent to take part in the study and the methods were reviewed and approved by the
104 Institutional Review Board at the University of Louisiana at Lafayette.

105

106 2.2 Procedures

107 The investigation was conducted to determine if 14 days of supplementation with *Pinus P.*
108 leading up to an exercise test with and additional two days of post exercise supplementation would
109 increase performance and reduce biomarkers associated with muscle damage, inflammation and
110 oxidative stress. During the initial visit, participants gave written informed consent after having had
111 the experimental procedures explained to them. Afterwards, they will filled out a health
112 questionnaire, the PAR-Q+, and the Leisure and Physical Activity Survey [26]. Based upon these
113 surveys, the participants were deemed fit to continue with the experimental procedures. The
114 participants also completed the ASA 24 (Automated Self-Administered 24-hour Recall) diet
115 questionnaire, from which no dietary deficiencies were noted. The participants were then asked to
116 maintain a diet consistent with the 24-hour recall from this point in the study forward.

117 Following completion of the questionnaires, participant's height and weight was determined
118 via stadiometer, and body fat percentage were measured using air displacement plethysmography
119 (Bod Pod Gold Standard System, Rome, Italy). Finally, to finish data collection on the initial visit the
120 participants underwent a VO_2 peak test on a cycle ergometer. The test consisted of a 25 watt ramp

121 protocol on a COSMED E100 P. During this test expired gases was collected continuously as well
122 as heart rate and SpO₂ using a COSMED QUARK CPET. The participant continued to exercise until
123 their VO₂ failed to increase by 100ml/min for an increase in wattage or volitional failure occurred.

124

125 2.2.1 Assignment of Order

126 Participants were randomly assigned to an order of treatment (*Pinus P.* and placebo). The
127 study will be conducted double-blind, 16 days (14 pre – exercise, 2 days post exercise) were pre-
128 packaged into coded bottles (unique numeric codes) and provided to participants. The participants
129 were asked to take 4 pills per day during the 14 days leading up to the exercise trial and the 2 days
130 after. This delivered a 200mg per day dose of *Pinus P.* Participants received their first doses after
131 initial visit and were reminded that exercise was restricted 48 hours prior to the exercise trial until
132 the end of the 48 hour follow up visit.

133

134 2.3 Pre-Exercise Trial Visit

135 The participants were asked to report to the Human Performance Lab in the evening prior to
136 the exercise trials. The participants were feed a standard meal for the evening (pre-packaged to
137 maintain consistency) and sent home with a 240 calorie evening snack consisting of 10g of protein,
138 41g of carbohydrates, and 4g of fat. The participants were provided with an actigraph sleep monitor
139 to wear and asked to note the time they went to bed. The data from this monitor was collected the
140 next morning prior to the start of the exercise trial. Finally, from this point until the end of the 48-
141 hour follow up NSAIDS (non-steroidal anti-inflammatory drugs) were restricted due to the
142 measurement of inflammatory markers.

143

144 2.4 Exercise Trials

145 Participants reported in the morning hours (0600-0800) fasted. They had blood drawn from the
146 antecubital space (pre-exercise sample) and then repeated the 25-watt ramp protocol similarly to the
147 VO₂ peak test. During this trial expired gases were monitored in a similar fashion, and additionally
148 near-infrared spectroscopy (NIRS) sensors (Moxy Oxygen Monitor 3, Hutchinson, MN) were secured
149 to the quadriceps muscles, one to the vastus lateralis and another to the vastus medialis, to monitor
150 muscle oxygenation. Participants exercised until volitional failure. One-hour post exercise
151 participants again donated a blood sample from the antecubital space. Participants were given water
152 to drink during the recovery phase and were reminded to continue to take their assigned doses
153 through the 24 and 48 hour recovery visits. Participants were also reminded that the restrictions on
154 NSAIDS and exercise are also active through the conclusion of the 48 hour follow up. The participants
155 had a one week wash-out period prior to beginning the next supplementation phase with the
156 opposite treatment.

157

158 2.4.1 24 and 48 hour Follow-Up Visits

159 Participants reported to the lab in the morning hours fasted (0600-0800) and again donated a
160 blood sample from the antecubital space. Following this muscle pain was assessed using an
161 algometer. This is a device that provides a constant low force pressure (50N) to a small (1cm diameter)
162 surface. The use of these devices enhances the collection of post-exercise muscle soreness and is an
163 improvement over the traditional method of using visual analogue scales alone. Three specific

164 locations were used, the vastus lateralis 25% and 50% of the distance between the superior border of
165 the patella and greater trochanter of the femur, the vastus medialis 25% of the distance between these
166 same landmarks. The exact locations of the tests were marked with a permanent marker and the
167 participants was given a marker to maintain the marks with for the remainder of the study.

168

169 2.5 Blood Collection

170 Blood donated by the participants during the study was collected in 7.5 ml serum separator
171 tubes. This was allowed to stand at room temperature for 15 minutes then centrifuged at 4° C at 3500
172 rpm for 10 minutes. Supernatant was removed and stored in micro-centrifuge tubes for later analysis.

173 Serum was analyzed for oxidative stress via MDA/TBARS colorimetric assays. Additionally
174 serum was tested for Lactate Dehydrogenase and Creatine Kinase activity via colorimetric assays to
175 examine muscle damage. The absorption endpoints of these assays was read with a BioTek ELX 808
176 microplate reader with Gen5 software for data analysis.

177 Finally, a multiplex chemiluminescent assay was run to examine inflammation (IL-1 α , IL-1 β , IL
178 2, IL 4, IL 6, IL 8, IL 10, INF- γ , TNF- α). At the conclusion of the assay procedures the plate was imaged
179 with a CCD imager (18 megapixel) and the data analyzed with Qview Pro Software.

180

181 2.6 Statistical Analysis

182 The principal investigator entered all data into JMP 11.0 pro software at the conclusion of the
183 study. Data was grouped according to research question and analyzed via repeated measures Anova
184 with post-hoc analysis where necessary or via non-parametric means provided data deviated from a
185 normal distribution. Statistical significance was set a priori at alpha <0.05 and trend in the data at
186 alpha <0.10.

187 3. Results

188 3.1 Human Performance Data

189 3.1.1 Oxygen Consumption, Muscle Oxygenation and Power from exercise trials

190 Anova did not reveal a significant difference between maximum VO₂ achieved during the 25
191 watt ramp protocols by treatment type (F=0.482, p=0.492 *Pinus P.*: 25.8 +/- 4.8 ml O₂/kg*min Placebo:
192 27.2 +/- 6.9 ml O₂/kg*min). Similarly, statistical Analysis of muscle oxygenation data from NIRS
193 sensors (F=0.833, p=0.367) and Total Hemoglobin (blood flow) (F= 0.610, p=0.439) did not reveal and
194 significant difference by treatment during the exercise trial. Finally, Anova did not reveal a
195 significant difference between watts (power) achieved during the 25 watt ramp protocols by
196 treatment type (F=0.571, p=0.454 *Pinus P.*: 189 +/- 34.8ml O₂/kg*min Placebo: 181.3 +/- 29.8 ml
197 O₂/kg*min).

198

199 3.1.2 Muscle Pain at 24 and 48 hours

200 Vastus Lateralis 25% of the distance between the superior border of the patella and greater
201 trochanter of the femur on the right leg did not reveal any main effects for treatment (F=0.111,
202 p=0.742) nor interaction effects for treatment*time (F=1.34, p=0.253). Vastus Lateralis 25% of the
203 distance between the superior border of the patella and greater trochanter of the femur on the left leg
204 did not reveal any main effects for treatment (F=0.756, p=0.390) nor interaction effects for
205 treatment*time (F=0.352, p=0.555).

206 Vastus Lateralis 50% of the distance between the superior border of the patella and greater
207 trochanter of the femur on the right leg did not reveal any main effects for treatment ($F=0.237$,
208 $p=0.628$) nor interaction effects for treatment*time ($F=0.002$, $p=0.960$). Vastus Lateralis 50% of the
209 distance between the superior border of the patella and greater trochanter of the femur on the left leg
210 did not reveal any main effects for treatment ($F=0.125$, $p=0.724$) nor interaction effects for
211 treatment*time ($F=0.593$, $p=0.446$).

212 Vastus Medialis 25% of the distance between the superior border of the patella and greater
213 trochanter of the femur on the right leg did not reveal any main effects for treatment ($F=0.052$,
214 $p=0.821$) nor interaction effects for treatment*time ($F=0.640$, $p=0.428$). Vastus Medialis 25% of the
215 distance between the superior border of the patella and greater trochanter of the femur on the left leg
216 did not reveal any main effects for treatment ($F=0.002$, $p=0.9617$) nor interaction effects for
217 treatment*time ($F=0.001$, $p=0.966$).

218

219 3.2 Biomarkers of Muscle Damage

220 3.2.1 Creatine Kinase (CK) and Lactate Dehydrogenase

221 Analysis of Creatine Kinase data from collected serum did not reveal a main effect for treatment
222 ($F=0.172$, $p=0.681$) nor an interaction effect for treatment*time ($F=0.223$, $p=0.878$). Analysis of Lactate
223 Dehydrogenase data from collected serum did not reveal a main effect for treatment ($F=0.114$,
224 $p=0.737$) nor an interaction effect for treatment*time ($F=1.57$, $p=0.213$).

225

226 3.2.2 Multiplex Inflammatory Panel

227 Analysis of IL-1a, IL-1b, IL-2,4,6,8,10, INF γ and TNF α data from collected serum did not reveal
228 a main effect for treatment ($F<1.0$, $p>0.4$) nor an interaction effect for treatment*time ($F<1.2$, $p>0.3$).

229

230 3.2.4 Oxidative Stress Results

231 Analysis via Repeated Measures Anova was undertaken, however the assumption of Anova that
232 residuals will be normally distributed was violated. Therefore, analysis was undertaken with non-
233 parametric means. Chi-square analysis demonstrated that the 48 hour time point was significantly
234 reduced with *Pinus P.* as compared to placebo. (ChiSq = 2.63, $p=0.05$). The mean for the placebo group
235 ($\bar{x} = 0.99\text{nmol/ml}$, $SD = 0.44$), and the mean for the *Pinus P.* group ($\bar{x} = 0.76\text{nmol/ml}$, $SD = 0.38$).

236 4. Discussion

237 Exercise produces an imbalance between reactive oxygen species (ROS), free radicals and
238 antioxidants [27,28]; this phenomenon is referred to as oxidative stress. Both acute aerobic [29] and
239 anaerobic [30] exercise has the potential to increase free radical production. During low-intensity and
240 duration protocols, antioxidant defenses appear sufficient, but as intensity and duration increase, this
241 is no longer the case [31]. In muscle tissue, eccentric exercises both simple, like arm curls [32] or more
242 complex, as with downhill hill running [33], demonstrate increases in oxidative stress within the
243 blood plasma. It appears that antioxidant capacity may be temporarily reduced during and
244 immediately post exercise [34], after which time, levels typically increase above basal conditions
245 during the recovery period [35]. In the present study, this response took 24 to 48 hours, as with other
246 studies of post-sprint type exercises [36], or immediately, in post-endurance marathon runners [36].

247 A few studies have missed these changes by taking only one sample immediately post-exercise [37],
248 or 20 minutes post-exercise [38]

249 Conversely, chronic exercise is the same stimulus that is necessary for an up-regulation in
250 endogenous antioxidant defenses [28]. In two studies of exercise trained mice, 8-weeks of exercise, at
251 a rate 3 or more times a week, demonstrated changes in the mitochondria associated with reduced
252 effects of oxidative stress at the 48-hour mark post-exercise [39]. However, prolonged physical
253 activity also produces an excess amount of reactive oxidative species[40], beyond the ability of the
254 body's ability to cope under normal physiological circumstances[41]. Chronic, heavy physical
255 exercise characterized by remarkable increase in oxygen consumption presents a challenge to the
256 antioxidant systems because of the increase production of ROS due to the increased consumption of
257 Vitamin E [42]. The subsequent free radical damage can hamper other body systems if not countered
258 by exogenous supplementation such as *Pinus P.* Oxidative stress facilitates peroxidation of low-
259 density lipoproteins (LDL) cholesterol, which leads to cytotoxicity and enhanced coronary artery
260 plaque formation [43,44]. It is also involved in many other pathophysiological states including aging,
261 neurodegenerative diseases, and cancer [28]. Certain metabolic conditions and infections, such *H.*
262 *pylori*, increase the production of reactive oxygen species, which, in turn, can lead to the breakdown
263 of the gastric lining, a precursor to gastric cancer [45].

264 Additional oral antioxidant supplementation, especially Vitamins C and E, may be a suitable,
265 non-invasive means of reducing oxidative stress, but excess exogenous antioxidants may have
266 detrimental effects on health and performance [28]. Alternatives to supplementation include whole
267 foods that contain antioxidants in natural ratios and proportions [28]. An adequate intake of vitamins
268 and mineral through a varied diet remains an optimal approach[28]. However, food availability,
269 intolerance to certain types of foods, and extreme training regimens where athletes are exposed to
270 high oxidative stress, make exogenous supplementation with *Pinus P.* and other antioxidants
271 necessary.

272 5. Conclusions

273 The primary finding of the present investigation was that *Pinus P.* as compared to placebo was
274 effective at affording protection from oxidative stress post exercise. It is suggested that further work
275 be undertaken to evaluate these findings with other exercise modes known to greatly increase lipid
276 peroxidation (marathon, triathlon, road races >10k) and also it could be suggested that clinical
277 evidence be garnered from a study of individuals with metabolic syndrome, as that is known to
278 greatly enhance oxidative stress.

279

280 **Funding:** This research was funded by Horphag research grant number R4498

281 **Conflicts of Interest:** The authors declare no conflict of interest

282

283 **References**

- 284 1. Chevion, M. et al. Human studies related to protein oxidation: protein carbonyl content as a marker of
285 damage. *Free Radic Res* **2000**, *33*, Suppl:S99.
- 286 2. Lee, J. et al. Eccentric exercise effect on blood oxidative-stress markers and delayed onset of muscle
287 soreness. *Med Sci Sports Exerc* **2002**, *34*, 443.
- 288 3. Powers, S.K.; Jackson, M.J. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle
289 force production. *Physiol Rev* **2008**, *4*, 1243-76.
- 290 4. Chen, P.; Song, F.; Lin, L.-Z. Chromatographic fingerprint analysis of Pycnogenol dietary supplements. *J*
291 *AOAC Int* **2009**, *92*, 624–632.
- 292 5. Rohdewald, P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with
293 a diverse clinical pharmacology. *Int J Clin Pharmacol Ther* **2002**, *40*, 158–168.
- 294 6. Carr, A.; Frei, B. The role of natural antioxidants in preserving the biological activity of endothelium-
295 derived nitric oxide. *Free Radic. Biol. Med.* **2000**, *28*, 1806–1814.
- 296 7. Fitzpatrick, D. F.; Bing, B.; Rohdewald, P. Endothelium-dependent vascular effects of Pycnogenol. *J.*
297 *Cardiovasc. Pharmacol.* **1998**, *32*, 509–515.
- 298 8. Nishioka, K. et al. Pycnogenol, French maritime pine bark extract, augments endothelium-dependent
299 vasodilation in humans. *Hypertens. Res.* **2007**, *30*, 775–780.
- 300 9. Uhlenhut, K.; Högger, P. Facilitated cellular uptake and suppression of inducible nitric oxide synthase by
301 a metabolite of maritime pine bark extract (Pycnogenol). *Free Radic. Biol. Med.* **2012**, *53*,305–313.
- 302 10. Noda, Y. et al. Hydroxyl and superoxide anion radical scavenging activities of natural source
303 antioxidants using the computerized JES-FR30 ESR spectrometer system. *Biochem. Mol. Biol. Int.* **1997**,
304 *42*, 35–44.
- 305 11. Packer, L.; Rimbach, G.; Virgili, F. Antioxidant activity and biologic properties of a procyanidin-rich
306 extract from pine (*Pinus maritima*) bark, pycnogenol. *Free Radic. Biol. Med.* **1999**, *27*, 704–724.
- 307 12. Iravani, S.; Zolfaghari, B. Pharmaceutical and nutraceutical effects of *Pinus pinaster* bark extract. *Res*
308 *Pharm Sci* **2011**, *6*, 1–11.
- 309 13. Sivonová, M. et al. The effect of Pycnogenol on the erythrocyte membrane fluidity. *Gen. Physiol.*
310 *Biophys.* **2004**, *23*, 39–51.
- 311 14. Voss, P.; Horakova, L.; Jakstadt, M.; Kiekebusch, D.; Grune, T. Ferritin oxidation and proteasomal
312 degradation: protection by antioxidants. *Free Radic. Res.* **2006**, *40*, 673–683.
- 313 15. Enseleit, F. et al. Effects of Pycnogenol on endothelial function in patients with stable coronary artery
314 disease: a double-blind, randomized, placebo-controlled, cross-over study. *Eur. Heart J.* **2012**, *33*, 1589–
315 1597.
- 316 16. Golański, J. et al. Does pycnogenol intensify the efficacy of acetylsalicylic acid in the inhibition of platelet
317 function? In vitro experience. *Postepy Hig Med Dosw (Online)* **2006**, *60*, 316–321.
- 318 17. Koch, R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. *Phytother*
319 *Res* **2002**, *16 Suppl 1*, S1-5.
- 320 18. Trebatická, J. et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. *Eur Child*
321 *Adolesc Psychiatry* **2006**, *15*, 329–335.
- 322 19. Luzzi, R. et al. Pycnogenol® supplementation improves cognitive function, attention and mental
323 performance in students. *Panminerva Med* **2011**, *53*, 75–82.
- 324 20. Hasegawa, N. Stimulation of lipolysis by pycnogenol. *Phytother Res* **1999**, *13*, 619–620.
- 325 21. Mochizuki, M.; Hasegawa, N. Pycnogenol stimulates lipolysis in 3t3-L1 cells via stimulation of beta-
326 receptor mediated activity. *Phytother Res* **2004**, *18*, 1029–1030.
- 327 22. Lee, O.-H.; Seo, M.-J.; Choi, H.-S.; Lee, B.-Y. Pycnogenol® inhibits lipid accumulation in 3T3-L1
328 adipocytes with the modulation of reactive oxygen species (ROS) production associated with antioxidant
329 enzyme responses. *Phytother Res* **2012**, *26*, 403–411.
- 330 23. Liu, X.; Zhou, H.-J.; Rohdewald, P. French maritime pine bark extract Pycnogenol dose-dependently
331 lowers glucose in type 2 diabetic patients. *Diabetes Care* **2004**, *27*, 839.
- 332 24. Zibadi, S.; Rohdewald, P. J.; Park, D.; Watson, R. R. Reduction of cardiovascular risk factors in subjects
333 with type 2 diabetes by Pycnogenol supplementation. *Nutr Res* **2008**, *28*, 315–320.
- 334 25. Parveen, K.; Khan, M. R.; Mujeeb, M.; Siddiqui, W. A. Protective effects of Pycnogenol on hyperglycemia-
335 induced oxidative damage in the liver of type 2 diabetic rats. *Chem. Biol. Interact.* **2010**, *186*, 219–227.
- 336 26. Bellar, D.M.; Judge, L.W.; Peterson, J.; Bellar, A.; Bryan, C. Exercise and academic performance among
337 nursing and kinesiology students at US colleges. *J Educ Health Promot* **2014**, *3*, 9.
- 338 27. Urso, M.; Clarkson, P.M. Oxidative stress, exercise and antioxidant supplementation. *Toxicology* **2003**,
339 *189*, 41-54.

- 340 28. Pingitore, A. et al. Exercise and oxidative stress: potential effects of antioxidant dietary strategies in
341 sports. *Nutrition* **2015**, *31*, 916-922.
- 342 29. Davies, K.J.; Quintanilha, A.T.; Brooks, G.A., Packer, L. Free radicals and tissue damage produced by
343 exercise. *Biochem Biophys Res Commun* **1982**, *107*, 1198-1205.
- 344 30. Bailey, D.M. et al. Regulation of free radical outflow from an isolated muscle bed in exercising humans.
345 *Am J Physiol Heart Circ Physiol* **2004**, *287*, H1689-99.
- 346 31. Knez, W.L.; Jenkins, D.G.; Coombes, J.S. Oxidative stress in half and full Ironman triathletes. *Med Sci*
347 *Sports Exerc* **2007**, *29*, 283-288.
- 348 32. Lee, J. et al. Eccentric exercise effect on blood oxidative-stress markers and delayed onset of muscle
349 soreness. *Med Sci Sp Exerc* **2002**, *34*, 443-448.
- 350 33. Byrne, W.C. et al. Delayed onset soreness following repeated bouts of downhill running. *J Appl Physiol*
351 **1985**, *59*, 710-715.
- 352 34. Steinburg, J.G.; Delliaux, S.; Jammes, Y. Reliability of different blood indices to explore the oxidative
353 stress in response to maximal cycling and static exercises. *Clin Physiol Funct Imaging* **2006**, *26*, 106-112.
- 354 35. Nikolaidis, M.G. et al. Acute exercise markedly increases blood oxidative stress in boys and girls. *Appl*
355 *Physiol Nutr Metab* **2007**, *32*, 197-205.
- 356 36. Marzatico, F.; Pansarasa, O.; Bertorelli, L.; Somenzini, G.; Della Valle, G. Blood free radical antioxidant
357 enzymes and lipid peroxides following long-distance and lactacidemic performances in highly trained
358 aerobic and sprint athletes. *J. Sports Med Phys Fitness* **1997**, *37*, 235-239.
- 359 37. Alessio, H.M.; Goldfarb, A.H.; Coa, G. Exercise-induced oxidative stress before and after vitamin C
360 supplementation. *Int J Sport Nutr* **1997**, *7*, 1-9.
- 361 38. Waring, W.S. et al. Uric acid reduces exercise-induced oxidative stress in healthy adults. *Clin Sci (Lond)*
362 **2003**, *105*, 425-430.
- 363 39. Silva, L. et al. Physical exercise increases mitochondrial function and reduces oxidative damage in
364 skeletal muscle. *Euro J Appl Physiol* **2009**, *105*, 861-867.
- 365 40. Tromm, C. B. et al. Effect of different frequencies weekly training on parameters of oxidative stress. *Brazil*
366 *J of Kinan and Human Perf* **2012**, *14*, 52.
- 367 41. Ji, L. Oxidative stress during exercise: Implication of antioxidant nutrients. *Free Rad Biol Med* **1995**, *18*,
368 1079-1086.
- 369 42. Machlin, L.; Bendich, A. Free radical tissue damage: Protective role of antioxidant nutrients. *FASEB* **1987**,
370 *1*, 441-445.
- 371 43. Luc, G. et al. Oxidation of lipoproteins and atherosclerosis. *Am J Clin Nutr* **1991**, *55*, S265.
- 372 44. Steinberg, D. L. et al. Beyond cholesterol modification of low density lipoprotein that increases its
373 atherogenicity. *N Engl J Med* **1989**, *320*, 915.
- 374 45. Handa, O.; Naito, Y.; Yoshikawa, T. Redox biology and gastric carcinogenesis: the role of *Helicobacter*
375 *pylori*. *Redox Rep* **2011**, *16*, 1-7.